Mayo Clinic 144例胚系易感综合征患者的血液系统恶性肿瘤谱、克隆演化与结局
本研究呈现144例Mayo Clinic胚系易感综合征(GPS)患者的临床与基因组数据,其中59例通过算法诊断前瞻性评估。体细胞NGS检测识别GPS患者的克隆演化,ASXL1、RAS通路基因、SRSF2和TET2突变最常见。
要点
- GPS患者涵盖IBMFS、伴或不伴前驱血小板减少的GPS及一般癌症易感综合征,血液肿瘤谱广泛。
- 体细胞NGS可识别GPS患者克隆演化,ASXL1、RAS通路基因、SRSF2和TET2突变最常见。
- 前瞻性GPS识别使91%患者管理改变,包括筛查、HSCT评估、用药调整和遗传咨询。
核心结论
- GPS患者血液系统恶性肿瘤谱广泛,体细胞NGS可识别克隆演化,前瞻性GPS识别可显著改变管理。
研究设计与样本
- 研究纳入144例Mayo Clinic GPS患者,其中59例在专门GPS/IBMFS门诊采用算法诊断前瞻性评估。
主要发现
- 27例(19%)为伴前驱血小板减少的GPS,包括RUNX1-FPD 15例、ANKRD26 6例、ETV6 2例、GATA1 1例和MPL 3例。
- 28例(19%)为不伴前驱血小板减少的GPS,包括GATA2单倍剂量不足16例、DDX41 10例、CBL 1例和CEBPA 1例。
- 17例(12%)为一般癌症易感综合征,包括共济失调毛细血管扩张症7例、杂合ATM变异3例、CHEK2 2例、TP53 2例、CDK2NA 1例、NF1 1例和Nijmegen断裂综合征1例。
- 纯合和杂合ATM致病变异仅与淋巴增殖性疾病相关,DDX41 GPS与淋巴增殖性疾病和髓系肿瘤相关;体细胞NGS检测显示ASXL1、RAS通路基因、SRSF2和TET2突变最常见。
临床怎么用
- 对血液肿瘤患者应开展专门GPS筛查、检测和管理项目,以识别GPS并调整管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Germline predisposition syndromes (GPS) result from constitutional aberrations in tumor suppressive and homeostatic genes, increasing risk for neoplasia in affected kindred. In this study, we present clinical and genomic data on 144 Mayo Clinic patients with GPS; 59 evaluated prospectively using an algorithm-based diagnostic approach in the setting of a dedicated GPS/ inherited bone marrow failure syndrome (IBMFS) clinic. Seventy-two (50%) patients had IBMFS (telomere biology disorders-32,Fanconi anemia-18, Diamond Blackfan Anemia - 11, congenital neutropenia-5, Schwachman-Diamond Syndrome-5 and Bloom Syndrome-1), 27 (19%) had GPS with antecedent thrombocytopenia (RUNX1-FPD-15, ANKRD26-6, ETV6-2, GATA1-1, MPL-3), 28 (19%) had GPS without antecedent thrombocytopenia (GATA2 haploinsufficiency-16, DDX41-10, CBL-1 and CEBPA-1) and 17 (12%) had general cancer predisposition syndromes (ataxia telangiectasia-7, heterozygous ATM variants-3, CHEK2-2, TP53-2, CDK2NA-1, NF1-1 and Nijmegen Breakage Syndrome-1). Homozygous and heterozygous ATM pathogenic variants were exclusively associated with lymphoproliferative disorders (LPD), while DDX41 GPS was associated with LPD and myeloid neoplasms. The use of somatic NGS-testing identified clonal evolution in GPS patients, with ASXL1, RAS pathway genes, SRSF2 and TET2 being most frequently mutated. Fifty-two (91%) of 59 prospectively identified GPS patients had a change in their management approach, including additional GPS-related screening in 42 (71%), referral for allogenic HSCT workup and screening of related donors in 16 (27%), medication initiation and selection of specific conditioning regimens in 14 (24%), and genetic counseling with specific intent of fertility preservation and preconceptual counseling in 10 (17%) patients; highlighting the importance of dedicated GPS screening, detection and management programs for patients with hematological neoplasms.
引用
- Martin ES, Ferrer A, Mangaonkar AA, et al. Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. Am J Hematol. 2021. PMID: 34390506. doi:10.1002/ajh.26321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。